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Introduction 
Choroidal osteoma is a rare ossifying benign tumor with 
unknown pathogenesis.1 It was first identified in 1978 by 
Gass et al.2 The tumor is generally unilateral and located in 
juxtapapillary and macular region. Although it occurs more 
frequently in young women, men and middle-aged people 
may also be affected.3,4 Despite being a benign tumor, it may 
cause serious vision loss due to pigment epithelium atrophy, 
serous retinal detachment, and most commonly choroidal 
neovascularization (CNV).3,5 While patients usually present 
with blurred vision, metamorphopsia, photophobia, and vision 
field defects, 8-30% of patients are asymptomatic.3,4 Choroidal 
osteoma is diagnosed by clinical examination. It appears in 
fundus examination as a slightly elevated, yellowish-white or 
orange-colored vascularized lesion with well-defined borders 
and pigment epithelium changes.3,4,6 Fundus autofluorescence, 
computed tomography, ultrasonography (USG), magnetic 
resonance imaging, optical coherence tomography (OCT), and 
fundus fluorescein angiography (FFA) assist diagnosis. Treatment 
targets complications. Here, we aimed to discuss a patient 
diagnosed with choroidal osteoma and secondary CNV who was 
treated with intravitreal ranibizumab. 
Case Report 
A 47-year-old female patient presented with complaints of 
decreased vision in her right eye. On examination, her visual 
acuity was 0.16 in the right eye and 1.0 in the left eye. Slit-lamp 
anterior segment examination and intraocular pressures were 
normal in both eyes. Fundus examination revealed a yellowish-
white lesion that had well-defined borders and was slightly 
raised from the surface of the retina located at macula of the right 
eye, while the left eye was normal (Figure 1A, B). FFA revealed 
early hyperfluorescence increasing in later stages and CNV in the 
region compatible with the lesion in the right eye (Figure 2A, 
B). B-scan USG in the right eye revealed a hyperechoic choroidal 
lesion causing acoustic shadowing (Figure 3). Spectral domain 
OCT revealed subretinal fluid in the right eye (Figure 4). Based 
on those findings, the patient was diagnosed with choroidal 
osteoma and secondary CNV. The patient was administered 
3 intravitreal ranibizumab injections at 1-month intervals. In 
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follow-up examination at 4 months post-injections, visual acuity 
had improved to 0.9 and OCT imaging showed regression of 
the subretinal fluid (Figure 5). Although the patient’s vision 
was stable during that period, a decline in visual acuity was 
observed 3 months later. An additional intravitreal ranibizumab 
injection was administered when the visual acuity in the right 
eye reached 0.4. At final follow-up 2 months after the injection, 
OCT revealed that the subretinal fluid had regressed, and visual 
acuity had improved to 0.8. The patient’s condition was stable 
during the 2-year follow-up period and no additional injections 
were required. 
Discussion
The main causes of vision loss in choroidal osteoma are 
the development of CNV, subfoveal fluid, and photoreceptor 
degeneration.5 CNV is seen more frequently among patients 
exhibiting a combination of hemorrhage and surface 
irregularities.5 Shields et al.3 observed CNV development in 
31% of their 61 choroidal osteoma patients, while Aylward et 
al.4 reported the incidence as 47% in their study of 36 patients. 
Although the mechanism by which CNV develops is not well 
understood, researchers have suggested that retinal pigment 
epithelium damage CNV in the underlying choroid, or that 
osteoma itself has neovascular membrane extensions.1,7 FFA and 
OCT are useful methods for identifying CNV. 
There is no standard method for the treatment of 
choroidal osteoma. Patients must be followed regularly and 
secondary complications must be treated as appropriate. In the 
management of CNV secondary to choroidal osteoma, partial 
success has been achieved using thermal laser photocoagulation 
and photodynamic therapy (PDT) for extrafoveal lesions, and 
transpupillary thermotherapy and PDT for subfoveal lesions. 
However, some studies showed that these treatment methods 
might leading to tumor decalcification, thus increasing retinal 
damage.8,9,10 
It is believed that laser photocoagulation may not have 
adequate efficacy in cases of CNV secondary to choroidal osteoma 
due to insufficient tumor melanine and a thinned, degenerated 
RPE-Bruch’s membrane complex.1 While PDT provides short-
term improvement in visual acuity, it has been demonstrated 
that retreatment may be necessary and final visual acuity may 
decline.11 Surgical removal of subfoveal CNV membranes results 
in favorable anatomic outcomes, but researchers have reported 
the procedure unsuccessful in terms of visual acuity.12
Another method employed in the treatment of these patients 
is intravitreal anti-vascular endothelial growth factor (anti-
VEGF). Bevacizumab and ranibizumab injections have been 
tested for this purpose, and positive outcomes were reported 
in both anatomy and visual acuity.5,6 It is thought that in 
choroidal osteoma cases, normal tissues are also damaged during 
the process, and VEGF expression is increased as a result of 
choroidal and retinal ischemic stress and chronic inflammation. 
RPE damage together with thinning of Bruch’s membrane and 
the choriocapillaris may contribute to the development of CNV. 
Thus, increased VEGF supports abnormal neovascularization. 
Therefore, anti-VEGF agents may be effective in treatment.13 
The first trials of intravitreal bevacizumab in the literature 
were conducted for this purpose and yielded favorable results.6,13 
In a case reported by Ahmadieh and Vafi,6 visual acuity 
Figure 1. A) Hypopigmented choroidal osteoma in the right macula, B) The left 
fundus appears normal
Figure 3. B-scan ultrasonography imaging of the right eye reveals a choroidal 
lesion causing acoustic shadowing
Figure 2. A) Fundus fluorescein angiography shows the osteoma area in the early 
phase, B) Increased active leakage in the late period in the area compatible with 
the osteoma
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improved from 20/200 to 20/20 after intravitreal bevacizumab 
injection and was preserved at this level throughout a 9-month 
follow-up period. In another case study from Kubota-Taniai et 
al.,13 visual acuity improved to 0.7 from 0.2 after bevacizumab 
injection and was preserved over the course of 4 years of 
follow-up. The highly effective responses obtained with anti-
VEGF injections were attributed to enhanced passage of the 
bevacizumab through the thinned and degenerated RPE and 
Sarıgül Sezenöz et al, Choroidal Osteoma and Secondary Choroidal Neovascularization
Figure 4. Pre-treatment optical coherence tomography imaging shows subretinal fluid and an area of choroidal neovascularization with a lesion situated in the cornea and 
optic shadowing behind it
Figure 5. The subretinal fluid is reduced after intravitreal ranibizumab injection
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Bruch’s membrane to the subretinal area, thus increasing the 
drug’s efficacy.6 
The first reported use of intravitreal ranibizumab injection 
for CNV secondary to choroidal osteoma was by Song and 
Roh5 in 2009; they found that CNV had regressed and visual 
acuity had improved from 20/200 to 20/100 at 6 months 
post-injection. In another case report, Gupta et al.14 observed 
CNV regression after ranibizumab injection and no recurrence 
was detected in 30 months of follow-up. Wu et al.15 reported 
a case in which visual acuity improved from 20/800 to 20/30 
after 3 injection and no recurrence was observed during 1.2 
years of follow-up. Mansour et al.16 demonstrated in their 
series consisting of 26 cases that intravitreal ranibizumab 
and bevacizumab were effective. In our case, visual acuity 
improved from 0.16 to 0.9 after 3 monthly injections. 
However, a decrease in visual acuity 3 months after the 
final injection and CNV recurrence necessitated another 
ranibizumab injection. 
In conclusion, although intravitreal ranibizumab injection is 
highly beneficial in the treatment of CNV secondary to choroidal 
osteoma in terms of visual acuity and anatomic recovery, 
recurrence may be observed, as our case also shows. Therefore, 
patients should be examined regular at monthly intervals, and 
treatment should be supported by repeated intravitreal anti-
VEGF injections when required.
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